The Food and Drug Administration (FDA) announced that it has accepted the supplemental New Drug Application (sNDA) for roflumilast foam 0.3% in adults and adolescents with scalp and body psoriasis ...

Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase III trial. Improvements in scalp itch were also greater for patients randomized ...

By Sneha S K April 27 (Reuters) - Oruka Therapeutics said on Monday that interim results showed its experimental drug helped clear psoriasis within 16 weeks, meeting the main goal of a mid-stage study ...

Emerging research presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting is reinforcing a critical shift ...

Credit: Arcutis. The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. By week 8, patients treated with roflumilast saw higher ...

Psoriasis isn’t just a skin condition — it’s an autoimmune disease that can affect your whole body and wellbeing. From medical treatments to lifestyle changes, there are more ways than ever to manage ...

Higher BMI, BMR, BSA, and weight correlate with more severe psoriasis and reduced treatment efficacy, particularly with biologic therapies. Personalized dosing strategies may be necessary for biologic ...

Please provide your email address to receive an email when new articles are posted on . Psoriasis on the scalp, face, palmoplantar areas, nails, intertriginous area and genitalia is often hard to ...

Once-daily 0.3% topical roflumilast foam significantly reduced severity in patients with psoriasis of the scalp and body over 8 weeks, with a favorable safety profile. “Use of roflumilast foam was ...